Combining Cancer Immunotherapies

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukemia patients. Further research into the underlying genetic pathways driving tumor proliferation uncovered additional oncoproteins that are critical for tumor maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumor responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumor regressions, but persistence is generally short-lived, limiting the overall clinical benefit.

    Related Conference of Combining Cancer Immunotherapies

    September 01-02, 2017

    4th International Conference on Parasitology

    Prague, Czech Republic
    November 2-3, 2017

    9th World Congress and Expo on Immunology

    Atlanta, Georgia, USA
    November 02-03, 2017

    9th World Congress on Immunity, Inflammation and Immunotherapies

    Atlanta, Georgia, USA
    November 06-07, 2017

    2nd International Conference on Autoimmunity

    Frankfurt, Germany
    November 08-09, 2017

    3rd Antibodies and Bio Therapeutics Congress & B2B

    Las Vegas, Nevada, USA
    November 13-14, 2017

    5th International Conference on HIV/AIDS, STDs and STIs

    Las Vegas, Nevada, USA
    Dec 14-15, 2017

    World Immunology Congress

    Dubai, UAE

    9th European Immunology Conference

    June 14-16, 2018 Rome, Italy

    Combining Cancer Immunotherapies Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in